Skip to content
i2E
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Menu
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Search

Patent protection: Extension helps

Get in Touch

By Sarah Terry-Cobo

Courtesy of The Journal Record

OKLAHOMA CITY – Lijun Xia and Rodger McEver received some good news about their cancer research this year. The patent they initially received for a possible leukemia treatment in 2004 was extended to 2024.

Patent protection is essential for helping get research out of the laboratory at the Oklahoma Medical Research Foundation, and eventually to patients battling cancer and other diseases.

The nonprofit OMRF doesn’t have the billion dollars needed to develop and test new therapies, President Stephen Prescott said. So it must work with pharmaceutical companies, which can invest in the discoveries made in OMRF’s lab to manufacture treatments at the scale needed for clinical trials.

It can take 15 years, on average, before a lab discovery is approved as a medicine or a treatment. When a scientist receives 20-year exclusivity rights on a treatment, that allows pharmaceutical companies time to develop the necessary manufacturing and clinical trial tests the U.S. Food and Drug Administration require before new drugs or treatments can be approved. This gives a pharmaceutical company a path to profitability, Prescott said.

The FDA regulatory process is expensive and time-consuming. Pharmaceutical companies must prove that discoveries in the lab don’t do more harm than good, which is particularly important for cancer treatments, said Jim Bratton, executive director of the University of Oklahoma Office of Technology Development.

“When researchers find new ways to crack the code, it’s encouraging for them to find ways to lengthen the opportunity for applying that innovation to a commercial setting,” he said.

Xia and McEver have discovered a way to make bone marrow transplants more successful. Their technology modifies stems cells found in umbilical cord blood to use in the transplants. However, there are challenges in getting those cells to work, Xia said.

One hurdle is getting stem cells to flow into the marrow once it is injected into the bloodstream. So the scientists found an enzyme that helps the blood cells hone in on and adhere to the marrow. Typically, cord blood cells adhere to bone marrow about 30 percent of the time. The discovery modifies cells so it adheres 99 percent of the time, he said.

When stem cells adhere to bone marrow, it can decrease recovery time and reduce the chance of infection or excessive bleeding, Xia said. Those savings can be dramatic for patients. A single day’s hospital stay in a bacteria-free environment necessary for bone marrow transplants can cost an average of $10,000.

The OMRF has a licensing agreement with Carlsbad, Calif.-based Targazyme to develop the enzyme on a commercial scale. The pharmaceutical company is working with MD Anderson to use the treatment in a clinical trial. Targazyme must raise more money to conduct a second phase of clinical trials.

But if the FDA approves the treatment, it could be used in more than just leukemia patients, Xia said. Stem cell treatment therapy can also be used to treat heart attack and stroke patients.

Bratton said patent protection helps foster the relationships between research institutions like OMRF or the OU Health Sciences Center and major pharmaceutical companies.

“We’re doing the out-of-the-box thinking, applying creative and innovative approaches to understand what is causing cancer to thrive or survive and proliferate,” he said.

The need to meet next quarter’s earnings expectations drives pharmaceutical companies to work with research institutions, which think about science holistically.

“It’s not just how do we kill the cancer, it’s how do we save the patient,” Bratton said.

Click here to read the article at the Journal Record website (subscription required).

 

 

Author

  • admin admin

More News

Loading...
woman in lab conducting a study
Blog, i2E
12.13.22

Bayesic Technologies Improves Effectiveness and Efficiency of Data Analysis in Healthcare

Read more
Bison grazing fields
Blog
11.30.22

Bison Underground Merges Nature, Science, and Technology to Tackle Climate Change

Read more
African American family sitting on couch reading and chatting
Blog, E3, i2E
11.22.22

Fokes Connects Families, Caregivers and Care Agencies for Smoother Communications and Care 

Read more
i2e blog post graphic
Blog, News
11.03.22

Introducing: Stories of Oklahoma Innovation

Read more
Default Featured Image
OKBio
06.28.22

Oklahoma Grown! i2E Invests in BIO startups

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma Medical Research Foundation BIO

Read more
Default Featured Image
OKBio
06.13.22

Moleculera Labs BIO

Read more
Default Featured Image
OKBio
06.13.22

University of Oklahoma Health Sciences Center BIO

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma State University BIO

Read more
Default Featured Image
OKBio
06.13.22

ECHO Investment Capital BIO

Read more
Default Featured Image
OKBio
06.13.22

AscendBioVentures BIO

Read more
Default Featured Image
OKBio
06.13.22

Dean McGee Eye Institute BIO

Read more
i2E

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
+1 (405) 235.2305

Tulsa Office

100 S. Cincinnati Ave – Suite 514
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources

© 2022 i2E Privacy Policy

Follow us:

Facebook Twitter Linkedin

Programs

  • E3
  • ACT Tulsa
  • Love's Entrepreneur's Cup
  • OKBio
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E